170 related articles for article (PubMed ID: 1674023)
1. Treatment of systemic vasculitis with pooled intravenous immunoglobulin.
Jayne DR; Davies MJ; Fox CJ; Black CM; Lockwood CM
Lancet; 1991 May; 337(8750):1137-9. PubMed ID: 1674023
[TBL] [Abstract][Full Text] [Related]
2. Pooled intravenous immunoglobulin in the management of systemic vasculitis.
Jayne DR; Lockwood CM
Adv Exp Med Biol; 1993; 336():469-72. PubMed ID: 8296659
[TBL] [Abstract][Full Text] [Related]
3. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin.
Tuso P; Moudgil A; Hay J; Goodman D; Kamil E; Koyyana R; Jordan SC
Am J Kidney Dis; 1992 Nov; 20(5):504-8. PubMed ID: 1442764
[TBL] [Abstract][Full Text] [Related]
4. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin.
Jayne DR; Esnault VL; Lockwood CM
J Autoimmun; 1993 Apr; 6(2):207-19. PubMed ID: 8499059
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.
Richter C; Schnabel A; Csernok E; De Groot K; Reinhold-Keller E; Gross WL
Clin Exp Immunol; 1995 Jul; 101(1):2-7. PubMed ID: 7621588
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.
Jayne DR; Chapel H; Adu D; Misbah S; O'Donoghue D; Scott D; Lockwood CM
QJM; 2000 Jul; 93(7):433-9. PubMed ID: 10874052
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin as sole therapy for systemic vasculitis.
Jayne DR; Lockwood CM
Br J Rheumatol; 1996 Nov; 35(11):1150-3. PubMed ID: 8948304
[TBL] [Abstract][Full Text] [Related]
8. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin.
Levy Y; Sherer Y; George J; Langevitz P; Ahmed A; Bar-Dayan Y; Fabbrizzi F; Terryberry J; Peter J; Shoenfeld Y
Int Arch Allergy Immunol; 1999 Jul; 119(3):231-8. PubMed ID: 10436395
[TBL] [Abstract][Full Text] [Related]
9. [Role of the titration of anti-neutrophil cytoplasmic antibodies in therapeutic follow-up of patients with systemic vasculitis].
Bergelin A; Subra JF; Carrere F; Chevailler A; Masson C; Szapiro N; Riberi P
Rev Med Interne; 1993; 14(10):1024. PubMed ID: 8009020
[TBL] [Abstract][Full Text] [Related]
10. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.
Gaskin G; Savage CO; Ryan JJ; Jones S; Rees AJ; Lockwood CM; Pusey CD
Nephrol Dial Transplant; 1991; 6(10):689-94. PubMed ID: 1754104
[TBL] [Abstract][Full Text] [Related]
11. High-dose pooled immunoglobulin in the therapy of systemic vasculitis.
Jayne DR; Lockwood CM
Trans Assoc Am Physicians; 1991; 104():304-12. PubMed ID: 1845155
[No Abstract] [Full Text] [Related]
12. Serum soluble interleukin 2 receptor levels in anti-neutrophil cytoplasmic autoantibodies--positive systemic vasculitis.
Lai KN; Lockwood CM
Postgrad Med J; 1993 Sep; 69(815):708-11. PubMed ID: 8255836
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.
Ito-Ihara T; Ono T; Nogaki F; Suyama K; Tanaka M; Yonemoto S; Fukatsu A; Kita T; Suzuki K; Muso E
Nephron Clin Pract; 2006; 102(1):c35-42. PubMed ID: 16174989
[TBL] [Abstract][Full Text] [Related]
14. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.
Jordan SC; Toyoda M
Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):31-8. PubMed ID: 8033432
[TBL] [Abstract][Full Text] [Related]
15. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis.
Nowack R; Grab I; Flores-Suarèz LF; Schnülle P; Yard B; van der Woude FJ
Nephrol Dial Transplant; 2001 Aug; 16(8):1631-7. PubMed ID: 11477166
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients.
Crickx E; Machelart I; Lazaro E; Kahn JE; Cohen-Aubart F; Martin T; Mania A; Hatron PY; Hayem G; Blanchard-Delaunay C; de Moreuil C; Le Guenno G; Vandergheynst F; Maurier F; Crestani B; Dhote R; Silva NM; Ollivier Y; Mehdaoui A; Godeau B; Mariette X; Cadranel J; Cohen P; Puéchal X; Le Jeunne C; Mouthon L; Guillevin L; Terrier B;
Arthritis Rheumatol; 2016 Mar; 68(3):702-12. PubMed ID: 26473632
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.
Martinez V; Cohen P; Pagnoux C; Vinzio S; Mahr A; Mouthon L; Sailler L; Delaunay C; Sadoun A; Guillevin L;
Arthritis Rheum; 2008 Jan; 58(1):308-17. PubMed ID: 18163506
[TBL] [Abstract][Full Text] [Related]
18. Systemic vasculitis treatment and monitoring update, 2008.
Yazici Y
Bull NYU Hosp Jt Dis; 2008; 66(3):228-30. PubMed ID: 18937637
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
Almroth G; Berlin G; Andersson B; Hahn-Zoric M
Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
[TBL] [Abstract][Full Text] [Related]
20. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.
Rossi F; Jayne DR; Lockwood CM; Kazatchkine MD
Clin Exp Immunol; 1991 Feb; 83(2):298-303. PubMed ID: 1993362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
